This ASX All Ords healthcare share more than doubled investors' money in a year. Here's why it's tipped to rocket another 55%

A leading broker forecasts another year of strong outperformance for this surging ASX All Ords healthcare stock.

Key points
  • Imricor Medical Systems has seen a remarkable 106% share price increase over the past 12 months, far outpacing the All Ordinaries Index's 10.3% gain.
  • The company's recent quarter highlighted major milestones, including regulatory submissions in the US and commercial launches in Europe, consolidating its leadership in MRI-guided cardiac ablations.
  • Analysts at Taylor Collison believe Imricor's platform could boost peak sales dramatically, maintaining an outperform rating on the ASX All Ords healthcare share.

The All Ordinaries Index (ASX: XAO) is unlikely to rocket 55% in the next 12 months, but this fast-rising ASX All Ords healthcare share looks well-placed to do just that.

That's according to the analysts at Taylor Collison, who recently maintained their outperform rating on Imricor Medical Systems Inc (ASX: IMR).

Imricor shares closed up 1.39% on Monday, trading for $1.46 apiece.

This sees the ASX All Ords healthcare share up 106% in 12 months, smashing the 10.3% gains delivered by the benchmark index over this same period.

Now, here's why Taylor Collison believes Imricor's bull run could have a lot further to go.

Concept image of a businessman riding a bull on an upwards arrow.

Image source: Getty Images

What's the latest from Imricor?

If you're not familiar with Imricor, the company describes itself as "leading the new field of real-time iCMR cardiac ablations – that is, cardiac ablations guided by real-time magnetic resonance imaging (MRI), rather than by conventional x-ray fluoroscopy".

The ASX All Ords healthcare share released its September quarter results on 22 October.

Commenting on the quarter just past, Imricor CEO Steve Wedan said on the day:

This was a milestone quarter for Imricor as we achieved parallel regulatory submissions in the US and launched NorthStar commercially in Europe. The 510(k) filings for both NorthStar and the Vision-MR Diagnostic Catheter represent major steps toward bringing MRI-guided electrophysiology to patients and physicians in the US.

Why this ASX All Ords healthcare share could keep leaping higher

Taylor Collison recently participated in the Atrial Fibrillation (AF) Symposium at the University of Adelaide in South Australia.

The broker called it "one of the world's premier forums for electrophysiology innovation".

And the AF Symposium bodes well for Imricor's growth outlook.

"Our engagements with key opinion leaders and industry participants provided strong validation of Imricor's real-time MRI-guided (iCMR) strategy," Taylor Collison said.

The broker added:

Industry and KOL discussions centred on atrial substrate visualisation, advances in AF ablation, and the accelerating commercial momentum in Pulse Field Ablation (PFA)—all areas where Imricor's platform offers a differentiated value proposition.

And this real time MRI guidance could see the ASX All Ords healthcare share doubling its peak sales.

Taylor Collison noted:

Expected benefits of real-time MRI guidance could allow IMR's workflow to move beyond AF re-dos & VT into initial AF ablations, potentially leading to greater total market uptake, boosting peak sales from US$1B – US$2B.

The broker estimates that the global electrophysiology market is worth around US$8 billion. But this market is reported to remain "dominated by X-ray and voltage mapping-based ablation, approaches constrained by limited soft-tissue visibility and persistently high recurrence rates".

Connecting the dots, Taylor Collison maintained its outperform rating on the ASX All Ords healthcare share with a price target of $2.26 a share. That's 55% above the Imricor closing share price on Monday.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

a young boy dressed in a business suit and wearing thick black glasses peers straight ahead while sitting at a heavy wooden desk with an old-fashioned calculator and adding machine while holding a pen over a large ledger book.
Broker Notes

Is the Xero share price too cheap to ignore?

If the company's growth plans stack up, this share could be one to watch.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Man putting coins in a wooden piggy bank next to piles of coins.
Broker Notes

Are NAB shares cheap or expensive? Brokers can't agree

The experts have their say after this week's profit report.

Read more »

Happy investor on tablet with finance graphs rising in overlay.
Broker Notes

Could Goodman and Paladin Energy shares rise 20% to 80%?

Let's see why these shares are being tipped to charge higher from current levels.

Read more »

Close-up of a business man's hand stacking gold coins into piles on a desktop.
Broker Notes

Clime Capital pays an 8.7% dividend yield. Pitt Street Partners says it's undervalued

A combination of dividends and capital gains could make this share one to watch.

Read more »

A man in a suit looks surprised as he looks through binoculars.
Broker Notes

These 3 ASX shares are on my watchlist for 2027

I've been on the hunt for value on the ASX.

Read more »

Piles of coins with rising arrows.
Broker Notes

I screened the ASX for five companies rated a strong buy by brokers

These companies could offer strong share price upside.

Read more »

Three small children reach up to hold a toy rocket high above their heads in a green field with a blue sky above them.
Broker Notes

2 ASX shares tipped by brokers to climb 110% or higher over the next 12 months

Brokers think these ASX shares could storm higher over the next 12 months.

Read more »